Domain-Specific AI Evaluation: Healthcare, Legal, and Financial Services

Why Generic Benchmarks Fail in Specialized Domains

Generic benchmarks test a model's ability to handle a broad range of tasks at a general level of quality. They are designed to be representative across contexts, which means they are not deeply representative of any specific context. A model evaluated on a general-purpose benchmark has demonstrated general capability. It has not demonstrated fitness for a specialized deployment.

The MEDFIT-LLM study (Rao, Jaggi, Naidu, IEEE RMKMATE 2025) provides a concrete illustration. The study developed a domain-specific evaluation framework for healthcare AI and found that model performance on general-purpose benchmarks did not reliably predict performance on healthcare-specific evaluation tasks. Models that appeared capable on general benchmarks showed specific gaps in medical reasoning, clinical context handling, and appropriate uncertainty expression that were only visible in domain-specific evaluation. This is not a surprising finding. It is the expected consequence of evaluating with instruments that were not designed for the task at hand.

The stakes of this mismatch are qualitatively different in specialized domains. A model that gives a slightly wrong answer to a general knowledge question is mildly unhelpful. A model that hallucinates a drug dosage, misinterprets a contract clause, or gives incorrect tax advice creates real harm: patient injury, legal liability, or financial loss. The severity of potential consequences in specialized domains demands evaluation that is calibrated to the domain's specific risks, not generic quality assessment.

Hallucination in High-Stakes Domains

Hallucination, the generation of plausible-sounding but factually incorrect content, is a general property of language models. In high-stakes domains, it is not a general quality issue. It is a specific risk that requires targeted evaluation and mitigation.

In clinical settings, hallucination affects three categories of output with distinct risks. Drug information hallucinations include incorrect dosages, wrong drug names, or fabricated interaction warnings. These are particularly dangerous because they sound authoritative and are difficult for non-specialists to verify. Diagnosis-related hallucinations involve the model suggesting conditions or tests that are not indicated, or failing to flag conditions that should be considered. Procedural hallucinations involve incorrect descriptions of clinical procedures, contraindications, or post-procedure requirements.

In legal contexts, hallucination takes different forms but carries equivalent risk. Case citation hallucination, where the model produces plausible-sounding but nonexistent case citations, is particularly insidious because it is difficult to detect without checking each citation and because legal documents citing fabricated cases have caused serious professional consequences. Statutory interpretation hallucination involves mischaracterizing what a law or regulation actually requires. Contract clause hallucination involves generating clauses that do not reflect the legal framework applicable to the parties or jurisdiction.

In financial services, hallucination risks include incorrect numerical calculations presented confidently, fabricated regulatory requirements, and mischaracterization of product terms or tax treatment. Each category requires domain-specific evaluation cases that test the specific hallucination types relevant to the deployment context.

Domain-specific evaluation is not more rigorous than general evaluation. It is differently rigorous, calibrated to the failure modes that create real harm in the specific deployment context.

Building a Domain-Specific Evaluation Framework

A domain-specific evaluation framework has five components: a domain-specific test set, domain-relevant metrics, domain-expert annotators, a regulatory alignment checklist, and a refresh cadence.

The domain-specific test set is the most critical component. It should include representative samples of the actual tasks the model will perform, deliberately including edge cases and the specific high-risk scenarios where failure would cause harm. For a healthcare model, this means including examples where the correct answer is "I cannot answer this safely without more clinical context." For a legal model, this means including examples where the correct answer involves flagging jurisdictional uncertainty.

Domain-relevant metrics measure the quality dimensions that matter in the domain. For healthcare, these include clinical accuracy, appropriate uncertainty expression, and safety-critical failure rate. For legal, they include citation accuracy, jurisdictional correctness, and appropriate scope limitation. For financial services, they include regulatory accuracy, numerical correctness, and suitability disclosure. These metrics overlap with generic quality dimensions but are calibrated to the specific properties that determine fit in each domain.

Domain-expert annotators are non-negotiable. A clinical AI model cannot be reliably evaluated by non-clinicians, even with an excellent rubric. The rubric helps, but identifying subtle clinical errors, appropriate hedging for specific types of medical questions, and the difference between a generally helpful response and one that is specifically unsafe for some patient populations requires clinical knowledge. The same principle applies in legal and financial evaluation.

Regulatory Alignment as an Evaluation Dimension

In regulated industries, evaluation must include regulatory alignment as an explicit dimension, not as an afterthought. The EU AI Act (Regulation EU 2024/1689) classifies AI systems by risk tier and imposes requirements proportional to risk. Systems in the high-risk category, which includes AI in healthcare, financial services credit scoring, employment, and other domains, must demonstrate accuracy, robustness, and cybersecurity through testing throughout their lifecycle.

The penalty structure creates strong incentives for rigorous evaluation. Violations of the prohibited practice provisions carry fines up to 7% of global annual turnover. Violations of provider and deployer obligations carry fines up to 3%. For a company with significant global revenue, these penalties dwarf the cost of evaluation infrastructure. The cost-benefit analysis for rigorous domain-specific evaluation is not close in regulated industries.

Beyond the EU AI Act, domain-specific regulatory requirements add evaluation obligations. The FDA's guidance on AI and machine learning-based software as a medical device (SaMD) specifies requirements for pre-deployment testing and post-market monitoring that functionally define evaluation standards. Financial services regulators in multiple jurisdictions have published guidance on model risk management that applies to AI models and specifies validation requirements. Building regulatory alignment into the evaluation framework from the start is more efficient than retrofitting compliance documentation after the model is built.

Temporal Validity and Refresh Cadence

Domain knowledge changes. Medical guidelines are updated as new evidence emerges. Laws are amended. Regulatory interpretations shift. A model trained on knowledge from two years ago may be giving advice that was correct then and is wrong now. Domain-specific evaluation must account for temporal validity, not just accuracy at a single point in time.

Evaluation test sets in rapidly changing domains need refresh cadences that match the domain's update velocity. Clinical guidelines in some therapeutic areas update multiple times per year. Tax regulations change annually and sometimes mid-year. A static evaluation set becomes stale quickly in these domains and will not catch the model's failure to reflect current guidance.

The practical implication is that domain-specific evaluation requires a process for updating test sets as domain knowledge changes, not just a one-time construction effort. This is more expensive than a static evaluation program, but it is the only way to know whether the model's domain-specific performance has degraded relative to current standards rather than relative to the standards that applied when the test set was built.

Cross-Domain Lessons

Despite their differences, healthcare, legal, and financial services AI evaluation share common structural lessons that generalize to other specialized domains.

First, expert annotators are the limiting resource. Building an evaluation program for a specialized domain requires either hiring domain experts or partnering with organizations that have them. This is often the largest cost in domain-specific evaluation, and it is a cost that cannot be engineered away. Generic annotators with domain training are not equivalent to domain experts, particularly for identifying subtle failures that require deep knowledge.

Second, the evaluation set must include safety-critical cases deliberately. Natural samples from typical usage will underrepresent the edge cases that cause the most harm, because users rarely ask the most dangerous questions. Safety-critical cases must be deliberately constructed and included in the evaluation set to ensure the model is tested against them.

Third, evaluation must connect to compliance documentation. In regulated industries, the evaluation process produces evidence of due diligence that has value beyond quality assurance. Maintaining evaluation records, documenting methodology, and preserving the link between evaluation findings and model changes creates a compliance artifact that supports regulatory engagement when needed.

Fourth, domain-specific evaluation is not a one-time event. It is an ongoing program that evolves with the model, with the deployment context, and with changes in domain knowledge and regulatory requirements. The infrastructure investment in domain-specific evaluation pays off over multiple model versions and deployment cycles, not just in the first deployment.

Starting a Domain-Specific Evaluation Program

If you are building a domain-specific evaluation program for the first time, the practical starting point is a gap analysis: what is the model being asked to do in this domain, what could go wrong, and what current evaluation covers those failure modes? The gap between "what could go wrong" and "what evaluation currently covers" defines the domain-specific evaluation program you need to build.

Prioritize the evaluation cases that correspond to the highest-severity failure modes. In healthcare, these are cases where incorrect model output could lead to patient harm. In legal, cases where the model produces advice that creates liability. In financial services, cases where incorrect output leads to regulatory violation or financial loss. These cases should be in the evaluation set regardless of how rare they are in typical usage, because the consequences of missing them are severe.

Build the evaluation program iteratively. Start with the highest-priority failure modes and expand coverage as resources allow. A focused domain-specific evaluation that covers the highest-severity failure modes is more valuable than a broad generic evaluation that does not specifically address domain risks. The goal is not exhaustive coverage. It is meaningful coverage of the cases that matter most for the deployment context.

The Role of Synthetic Data in Domain-Specific Evaluation

Obtaining real evaluation data in high-stakes domains is often constrained by privacy, confidentiality, and regulatory requirements. Patient records, legal documents, and financial data are subject to strict access controls that limit what can be included in evaluation datasets. Synthetic data generation offers one path to evaluation at scale: creating realistic but non-sensitive examples that cover the same distribution as real data without the access constraints.

The limitation of synthetic data is that it may not capture the full distribution of real-world examples, particularly the edge cases and unexpected inputs that cause the most interesting failures. A synthetic medical case generation process built on common clinical scenarios will likely produce evaluation data that underrepresents rare conditions, unusual presentations, and the kinds of complex multi-morbidity cases where AI support might be most valuable and most risky. Evaluation programs that rely exclusively on synthetic data may miss exactly the cases that matter most.

Hybrid evaluation programs that combine a core of real de-identified examples with synthetic data for coverage extension often strike a better balance. The real examples anchor the evaluation to genuine domain complexity. The synthetic examples extend coverage to scenarios that de-identified real data does not happen to include. Both types of data benefit from domain-expert review to verify that they represent realistic examples of the tasks the model will actually face.

Communicating Domain Evaluation Results to Non-Technical Stakeholders

Domain-specific evaluation results need to reach decision-makers who may not have technical backgrounds: clinical leadership, general counsel, chief risk officers, and board members who are responsible for approving AI deployments in regulated industries. Translating technical evaluation findings into language that supports these decisions without oversimplifying is a communication challenge that evaluation programs must address explicitly.

The most effective communication frames evaluation results in terms of the business and patient or client outcomes they protect. Instead of reporting that the model achieved 94.2% accuracy on the domain-specific test set, report that the model correctly handled 94.2% of the test cases, with the remaining 5.8% concentrated in the specific case categories that have been addressed with additional safeguards. Instead of reporting Cohen's kappa of 0.72 for inter-annotator agreement, report that qualified clinical reviewers agreed on output quality assessments at a rate that exceeds the minimum standard for reliable evaluation data.

Reporting must also address residual risk honestly. Stakeholders in regulated industries need to understand not just how the model performed in evaluation but what failure modes remain, what mitigations are in place, and what monitoring will detect if performance degrades in deployment. Evaluation results that communicate this level of specificity build the appropriate trust for deployment approval in high-stakes contexts, while results that report only positive metrics without characterizing residual risk create a false sense of certainty that can undermine trust when deployment reveals the expected imperfections.